Lonza, a global leader in contract development and manufacturing (CDMO) for the pharmaceutical and biotechnology industries, announced the expansion of its TheraPEAK product portfolio with the launch of AmpliCell Cytokines and the TheraPEAK 293-GT Medium System.

These additions are designed to strengthen Lonza’s GMP-grade solutions for the growing cell and gene therapy market, offering enhanced performance, consistency, and scalability from early-stage research through to clinical and commercial manufacturing.

Cytokines are a critical component in the manufacturing of cell therapies, playing an essential role in the expansion, activation, and differentiation of immune cells. The newly launched TheraPEAK AmpliCell Cytokines are produced using a mammalian expression system, ensuring high biological activity and native-like protein structure through proper folding and glycosylation. This results in superior biological relevance compared to bacterial systems, offering researchers and manufacturers improved batch-to-batch consistency and greater predictability in both research and GMP environments.

Also introduced is the TheraPEAK 293-GT Medium, a chemically defined, animal-origin-free solution tailored for adeno-associated virus (AAV) production in suspension HEK293 cells. Developed as a drop-in-ready system, the 293-GT Medium and its complementary supplement are engineered to integrate seamlessly with existing gene therapy workflows. Compatible with widely used transfection reagents and AAV enhancers, the system supports strong AAV titers and delivers high full-to-empty capsid ratios—key attributes for reliable and efficient gene therapy vector manufacturing.

Both the AmpliCell Cytokine range and the 293-GT Medium System align with Lonza’s commitment to regulatory-ready solutions. The TheraPEAK product line has been utilized in FDA-approved therapies and over 130 clinical trials worldwide, underscoring its proven performance and trust within the biopharmaceutical industry.

Mike Goetter, Head of Bioscience, Specialized Modalities at Lonza, commented, “The introduction of AmpliCell Cytokines and the 293-GT Medium to our TheraPEAK range greatly enhances our offering for cell and gene therapy customers. These new additions provide researchers and manufacturers with reliable, high-performance solutions that streamline development and support the advancement of transformative therapies.”